Compare IDAI & ITRM Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | IDAI | ITRM |
|---|---|---|
| Founded | 2016 | 2015 |
| Country | United States | Ireland |
| Employees | N/A | N/A |
| Industry | Computer Software: Prepackaged Software | Biotechnology: Pharmaceutical Preparations |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 20.9M | 24.3M |
| IPO Year | N/A | 2018 |
| Metric | IDAI | ITRM |
|---|---|---|
| Price | $3.72 | $0.42 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 1 | 1 |
| Target Price | ★ $12.00 | $9.00 |
| AVG Volume (30 Days) | 158.6K | ★ 1.2M |
| Earning Date | 11-14-2025 | 11-14-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $3,727,824.00 | $390,000.00 |
| Revenue This Year | $3.46 | N/A |
| Revenue Next Year | $219.85 | $325.95 |
| P/E Ratio | N/A | N/A |
| Revenue Growth | ★ 72.57 | N/A |
| 52 Week Low | $1.43 | $0.36 |
| 52 Week High | $18.75 | $2.18 |
| Indicator | IDAI | ITRM |
|---|---|---|
| Relative Strength Index (RSI) | 42.08 | 39.30 |
| Support Level | $4.00 | $0.44 |
| Resistance Level | $4.57 | $0.49 |
| Average True Range (ATR) | 0.34 | 0.04 |
| MACD | -0.05 | 0.01 |
| Stochastic Oscillator | 8.08 | 15.81 |
T Stamp Inc develops and markets identity authentication software solutions for enterprise partners and peer-to-peer markets. The company is engaged in developing proprietary artificial intelligence-powered solutions; researching and leveraging biometric science, cryptography, and data mining to deliver insightful identity & trust predictions while identifying and defending against fraudulent identity attacks, protecting sensitive user information, and extending the reach of digital services through accessibility. The artificial intelligence-powered solutions segment generates revenue principally from software licenses, professional services, and recurring Software-as-a-Service ("SaaS") revenue.
Iterum Therapeutics PLC is a pharmaceutical company dedicated to maximizing the commercial potential of Orlynvah, an oral-branded penem available in the United States and potentially the first and only oral and intravenous (IV) branded penem available globally. Its product Orlynvah has the potential to be a treatment for complicated urinary tract infections caused by the designated microorganisms, without the presence of known toxicities of some other antibiotics. The company operates in a single business segment, which is the development and commercialization of treatments for drug-resistant bacterial infections.